Reviewing Adaptive Biotechnologies Corporation (ADPT)’s and ADMA Biologics Inc. (NASDAQ:ADMA)’s results

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) and ADMA Biologics Inc. (NASDAQ:ADMA), both competing one another are Biotechnology companies. We will contrast their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Adaptive Biotechnologies Corporation 28 0.00 61.12M -0.44 0.00
ADMA Biologics Inc. 5 0.00 32.49M -1.34 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.


Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Adaptive Biotechnologies Corporation 220,172,910.66% 0% 0%
ADMA Biologics Inc. 711,034,271.46% -205.4% -62.4%


The Current Ratio and Quick Ratio of Adaptive Biotechnologies Corporation are 7.3 and 7.1 respectively. Its competitor ADMA Biologics Inc.’s Current Ratio is 4.6 and its Quick Ratio is 2.4. Adaptive Biotechnologies Corporation can pay off short and long-term obligations better than ADMA Biologics Inc.

Analyst Ratings

Adaptive Biotechnologies Corporation and ADMA Biologics Inc. Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Adaptive Biotechnologies Corporation 0 0 0 0.00
ADMA Biologics Inc. 0 0 2 3.00

Competitively ADMA Biologics Inc. has a consensus target price of $12.5, with potential upside of 195.51%.

Insider and Institutional Ownership

Roughly 46.2% of Adaptive Biotechnologies Corporation shares are held by institutional investors while 50.4% of ADMA Biologics Inc. are owned by institutional investors. Insiders held roughly 4.7% of Adaptive Biotechnologies Corporation’s shares. Competitively, insiders own roughly 7.7% of ADMA Biologics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Adaptive Biotechnologies Corporation -4.53% -3.87% 0% 0% 0% -4.34%
ADMA Biologics Inc. -2.43% -1.9% -19.2% 14.92% -42.36% 51.46%

For the past year Adaptive Biotechnologies Corporation has -4.34% weaker performance while ADMA Biologics Inc. has 51.46% stronger performance.


Adaptive Biotechnologies Corporation beats ADMA Biologics Inc. on 6 of the 10 factors.

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. ADMA Biologics, Inc. was founded in 2004 and is based in Ramsey, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.